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With recent advances in DNA sequencing technologies, fast acquisition of large-scale genomic data has 
become commonplace. For cancer studies, in particular, there is an increasing need for the classification 
of cancer type based on somatic alterations detected from sequencing analyses. However, the ever-
increasing size and complexity of the data make the classification task extremely challenging. In this 
study, we evaluate the contributions of various input features, such as mutation profiles, mutation 
rates, mutation spectra and signatures, and somatic copy number alterations that can be derived from 
genomic data, and further utilize them for accurate cancer type classification. We introduce a novel 
ensemble of machine learning classifiers, called CPEM (Cancer Predictor using an Ensemble Model), 
which is tested on 7,002 samples representing over 31 different cancer types collected from The Cancer 
Genome Atlas (TCGA) database. We first systematically examined the impact of the input features. 
Features known to be associated with specific cancers had relatively high importance in our initial 
prediction model. We further investigated various machine learning classifiers and feature selection 
methods to derive the ensemble-based cancer type prediction model achieving up to 84% classification 
accuracy in the nested 10-fold cross-validation. Finally, we narrowed down the target cancers to the six 
most common types and achieved up to 94% accuracy.
Cancer is a complex disease that refers to the phenomenon of abnormal cellular proliferation, invasion, or metas-
tasis in human tissues and blood. It is caused by the acquisition of a series of genomic alterations. Hence, an under-
standing of the genetic characteristics of cancer is crucial for accurate diagnosis and treatment. Next-generation 
sequencing techniques have recently been widely applied to cancer research to characterize various different types 
of genomic alterations in cancer genomes1–4. Large-scale cancer genome studies have revealed that the patterns of 
genomic alterations are often cancer type-specific. Lawrence et al. found that cancer mutations vary across cancer 
types, with genes mutated in a cancer-specific manner5. Hoadley et al. also confirmed that tissue-specific genomic 
features in cancers are the dominant signals for classifying cancer subtypes6. In addition, somatic copy number 
alterations and mutation spectra also display tissue-specific patterns7–9.
Using the tissue-specific nature of somatic alterations in cancer, a number of prediction methods for cancer 
type were recently developed by employing machine learning classifiers and various mutation features to improve 
classification accuracy. Marquard et al. used a random forest classifier (i.e., one-vs-rest (OvR) binary classifiers 
for multiclass classification) with a feature set consisting of somatic point mutations of known cancer-associated 
genes, mutation frequencies, and copy number profiles from the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database10 to identify tissues of origin11. The authors reported up to 85% maximum accuracy across 
six cancer types and 69% across 10 cancer types. Chen et al. used a support vector machine (SVM) classifier with 
official gene symbols, mutations, chromosome, and pathways as feature sets, which led to the maximum average 
accuracy of 62% across 17 cancer types12. Yuan et al. introduced a novel clustering-based feature selection scheme 
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with a deep neural network classifier (i.e., multilayer perceptron) for cancer classification13. In their work, only 
somatic point mutations were used for input feature data, which led to the maximum accuracy of 64% across 12 
cancer types. However, these previous studies have not fully assessed and exploited biologically meaningful input 
features and advanced machine learning techniques. Furthermore, most of them were able to handle only a small 
subset of the cancer types from the database for classification.
To address these problems, we propose a novel cancer type classification method, the Cancer Predictor using 
an Ensemble Model (CPEM) (see Fig. 1), which is based on the combination of advanced machine learning 
algorithms with various types of cancer somatic alterations and their derived features as input. To identify which 
input features are useful in classification, we conducted a comprehensive study on how various genetic altera-
tions, such as gene-level mutation profiles, mutation rates, mutation spectra and signatures, and gene-level copy 
number alterations affect the accuracy of the classifier and we discuss the biological reasoning behind this result. 
We further investigated the performance of various state-of-the-art machine learning classifiers, both for feature 
selection and for cancer classification, and developed a novel cancer type classifier based on an ensemble of deep 
neural network (DNN) and random forest classifiers. CPEM can classify a large number of cancer types with high 
accuracy (i.e., the average accuracy of 84% across 31 cancer types in the nested 10-fold cross-validation). When 
we focused on the six most common cancer types, we were able to achieve up to 94% average accuracy. To the 
best of our knowledge, the proposed method is the most accurate multiclass cancer type classification method 
yet-devised that is able to predict the largest class of cancer types, covering the entire cancer list in the TCGA 
database3.
Results
Experimental setup. All experiments were conducted using a workstation equipped with an Intel Xeon 
CPU E5-2640 CPU with four NVIDIA GTX 1080Ti GPUs. We used TensorFlow (version 1.9.0) to implement 
the proposed deep neural network. Our DNN architecture is a multi-layer perceptron with a multinomial class 
cross-entropy with a softmax loss function. We used the Rectified Linear Unit as the activation function.
Selecting the proper number of parameters and hidden layers (i.e., tuning hyperparameters) of the DNN is 
important for better prediction accuracy and faster training time. We empirically chose our DNN with three 
hidden layers where each layer has 2048 parameters. To train the neural network, we used the Adam optim-
izer14, a commonly used stochastic optimization algorithm for machine learning, with a learning rate of 10−5 and 
40% dropout per iteration to prevent overfitting. Other machine learning classifiers were implemented using the 
scikit-learn library15 in Python 3.6.1.
As shown in Fig. 2, the optimal number of input features and the feature selection method are chosen to 
maximize the accuracy over inner 10-fold cross-validation. Once feature selection is finalized, we tested the per-
formance of CPEM using the independent testing data that was not a part of the training data.
Efficacy of Various Mutation Features. To assess how each class of input feature affected the classifica-
tion accuracy, we used a random forest classifier as an initial prediction model and measured changes in clas-
sification performance as each feature was added using 10-fold cross-validation. Starting from the gene-level 
mutation profiles only, we consecutively added other feature groups, including mutation rates, mutation spectra, 
gene-level SCNAs, and mutation signatures, and measured the classification accuracy for each time. The accuracy 
for each feature group was 46.9%, 51.2%, 58.5%, 61.0%, and 72.7% respectively (Fig. 3a).
To further deduce the features that most contribute to the accuracy of the classification, we selected the top 
ten features based on the importance score from the classifier. These features included two mutation rates, one 
Figure 1. Overview of the CPEM cancer type prediction workflow. The first step in our workflow is building 
a set of feature vectors from the TCGA database. The feature vector consists of 22,421 gene-level mutation 
profiles, two mutation rates, six mutation spectra, 13,040 gene-level copy number alterations, and 96 mutation 
signatures. The next step is the feature vector dimension reduction by linear support vector classifier (LSVC)-
based feature selection. In the final step, the two machine learning classifiers which were trained by the same 
selected feature set (a deep neural network and a random forest) are combined to build an ensemble model for 
the final cancer type prediction.
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mutation signature (CCT.C > T), two mutation spectra (C > T, C > A) and five mutated genes [von Hippel-Lindau 
tumor suppressor (VHL); isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1); B-Raf proto-oncogene, ser-
ine/threonine kinase (BRAF); APC, WNT signaling pathway regulator (APC); KRAS proto-oncogene, GTPase 
(KRAS)] (Supplementary Fig. S1). This result is consistent with previous studies that identified distinct muta-
tional landscapes from many different types of cancer genomes8,9,16. For example, BRAF is involved in intracellu-
lar signaling associated with cell growth induction and is frequently mutated in some human cancers17. Acquiring 
mutations in KRAS is an essential step in the pathogenesis of many cancers18. This result confirms that genetic 
features play an important role in cancer initiation and progression, and also contribute to improving the accu-
racy of cancer classification. The biological meaning of this result will be discussed further in the ‘Discussion’.
Optimal Feature Selection. To choose the best feature selection method for our data, we tested the 
three most commonly used supervised feature selection algorithms—the extra tree-based, LASSO, and LSVM 
approaches. In this experiment, each feature selection method was applied to the same input feature set to reduce 
its size by 90% (i.e., only 10% of the input feature will be retained after selection), and the prediction accuracy of 
different classifiers using selected features was measured.
The accuracy of the three classifiers (i.e., ensemble, neural network, random forest) on the data processed by 
the three different supervised feature selection methods was compared (Fig. 3b; the inner 10-fold cross-validation 
results are shown using a boxplot). In general, the LASSO and LSVC selection methods performed well for the 
neural network classifier, and the extra tree-based selection method worked well for the random forest classifier. 
This is because LASSO and LSVC use the linear classifier similar to the perceptron model in the neural network, 
and extra tree-based selection is similar to the decision trees in a random forest. Of the LASSO and LSVC meth-
ods, LSVC displayed higher classification accuracy.
The performance of the classifier is affected by the selection method and by the number of selected features 
(i.e., the amount of feature dimension reduction). Figure 3c summarizes the classification accuracy for the differ-
ent number of selected features, measured using the inner 10-fold cross-validation. For 35,565 features, approx-
imately 4,000 to 8,000 selected features showed the best result, which is about 10% to 20% of the original feature 
set. By doing so, a higher accuracy could be achieved, up to a 2.34% increase in the outer 10-fold cross-validation, 
with less training time due to the small training set size.
Putting it all Together: CPEM Results
Based on the feature selection scheme and the optimal number of features found in the previous steps, we con-
struct the proposed ensemble-based cancer prediction model, CPEM. We have tested various combinations of 
classifiers and finally chosen a deep neural network and a random forest for our ensemble model. By combin-
ing two classifiers, we have reached up to 84% average accuracy on the testing data for 31 cancer types. This 
result is about 6 and 11 percentage points higher than the accuracy of conventional machine learning classifiers, 
such as fully-connected deep neural networks and random forests, respectively. Figure 4 shows the result of the 
outer 10-fold cross-validation for CPEM and the other classifiers, and Table 1 shows the detailed description of 
per-cancer type experimental result.
For better understandings of CPEM, we tested four well-known machine learning classifiers and further ana-
lyzed the correlation of the methods with each other. Table 2 shows the classification results of widely used clas-
sifiers, including DNN, OvR SVM, random forest, and k-nearest neighbors (KNN) clustering classifiers, in a 
pairwise fashion. In this table, A ∪ B is the probability that either A or B classifiers correctly predict the cancer 
type (total correct prediction), A ∩ B is the probability that both A and B classifiers correctly predict the can-
cer type (common correct prediction), and A−B and B−A are the probability that only either A or B predicts 
the result correctly. The classifiers were less correlated when A ∩ B was low and A−B and B−A were high. In 
Figure 2. Overview of the training and testing process of CPEM. We employ nested 10-fold cross-validation 
where the optimal feature selection is performed using the inner 10-fold cross-validation while the accuracy of 
the proposed method is evaluated using the outer 10-fold cross-validation. In the training step, two machine 
learning classifiers are trained with the same selected feature set by optimal feature selection. Note that we use 
the testing data that is not used in the feature selection optimization step in every iteration of the outer cross-
validation.
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addition, since we listed A and B in the table in descending order, it indicates that A is the better predictor (i.e., 
prediction accuracy is higher), so that B−A is the upper bound of the accuracy gain when the ensemble method 
is used. It is also important that the total correct prediction rate should be high (A ∪ B), and each classifier should 
predict higher than 50% accuracy (otherwise, it will impair the performance of the ensemble). In our experiment, 
we observed that the KNN clustering classifier performed worst, with only 48.59% prediction accuracy. It does 
not improve the accuracy when combined with other methods via ensemble. The random forest and OvR SVM 
performed similarly, with a respective prediction accuracy of 73.79% and 72.85%. Our DNN classifier outper-
formed all other classifiers, with a prediction accuracy of 82.25% which was approximately 10% higher than 
that of a random forest. The random forest classifier was slightly more accurate than the OvR SVM and was less 
correlated with DNN (i.e., lower A ∩ B). Therefore, the ensemble model combining the DNN and the random 
forest were the best choice. CPEM increased the accuracy of the DNN by 2%, which led to an average prediction 
accuracy of 84.09% for the 31 cancer types.
We also compared our method to existing machine learning-based cancer type classification methods. Since 
it is not practically feasible to use exactly the same training data used in other studies, we collected the data of the 
same cancer types used in other studies from our database and compared the accuracy reported in the literature 
(Table 3). For the cancer types used in TumorTracer11, we achieved up to 91.42% accuracy for six types (85% in 
TumorTracer) and 90.28% accuracy for ten types (69% in TumorTracer) (Supplementary Figs S4 and S5). When 
using the same 12 cancer types used in DeepGene13, we were able to achieve up to 84.66% accuracy, which was 20 
percentage points higher than that of DeepGene (64%) (Supplementary Fig. S6).
Figure 3. (a) Classification accuracy of a random forest classifier on each combination of feature groups. MP: 
Gene-level Mutation Profiles, Rate: Mutation Rates, Spec.: Mutation Spectra, SCNAs: Somatic Copy Number 
Alterations, Sig.: Mutation Signatures. (b) Comparison of feature selection methods. The boxplot shows the 
classifier accuracy measured by the inner 10-fold cross-validation for each feature selection method. It is shown 
that LSVC feature selection performs best on all three classifiers. (c) Classification accuracy for various feature 
sizes generated by the LSVC method. It is shown that the classification accuracy reaches its peak performance 
at around 4,000 to 8,000 features measured to optimize the DNN and random forest by the inner 10-fold cross-
validation.
Figure 4. Comparison of CPEM and other conventional machine learning classifiers. The boxplot shows the 
accuracy measured by the outer 10-fold cross-validation for each machine learning model after optimization 
through inner 10-fold cross-validation. The average classification accuracy of CPEM is about 6 and 11 
percentage points higher than those of a fully-connected deep neural network and a random forest, respectively.
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Discussion
We constructed various feature groups from the collected data and confirmed a maximum of 72.2% accuracy 
through a combination of features using an initial prediction model based on a random forest. Feature impor-
tance was calculated to identify elements with a high impact in a combination of features with maximum accu-
racy. The top ten features with the highest importance were of mutated genes
total of genes
#
#
, CCT.C > T mutation signature, VHL 
mutation, IDH1 mutation, C > T mutation frequency, C > A mutation frequency, BRAF mutation, of SNVs indels
Mb
# /
1
, 
APC mutation, and KRAS mutation (Supplementary Fig. S1). The frequency of mutation varies widely among 
samples according to the cancer type, ranging from 0.1 (pediatric cancer) to 100 (lung cancer) per Mb. High 
mutation frequencies are due to extensive exposure to well-known carcinogens, such as tobacco smoke (C > A 
mutation) and ultraviolet radiation (C > T mutation)9. We referred to the COSMIC10 data to identify signatures 
with a high frequency of CCT.C > T mutations, and confirmed that the frequency of CCT.C > T mutations was 
the highest in Signature 23 and 19. Signature 23 is present only in liver cancer samples, and Signature 19 is specific 
to pilocytic astrocytoma. According to the COSMIC data, VHL displayed mutation rates of 39% and 33% in liver 
cancer and paratesticular tissues, respectively. VHL is a transcription factor that plays a central role in the regula-
tion of gene expression by oxygen and is involved in ubiquitination and degradation of hypoxia-inducible-factor19. 
IDH1 catalyzes the conversion of isocitrate to alpha-ketoglutarate (aKG) in normal conditions. The 
cancer-associated IDH1 mutation converts aKG to 2-hydroxyglutarate (2HG)20. In gliomas and malignancies, 
IDH1 mutations induce postmenopausal changes and promote tumorigenesis21. The frequency of IDH1 muta-
tions in the COSMIC data is highest in the central nervous system (34%). BRAF is a crucial regulator of the 
extracellular signal-regulated kinase – mitogen activated protein kinase signaling pathway, leading to cell prolif-
eration, differentiation, and survival. BRAF mutations are present at a high frequency (8%) in various cancers, 
particularly in melanomas (50%)22. APC has a wide range of functions from the regulation of the WNT signaling 
Cancer type
Sample 
size
# of 
mutated 
genes
# of copy 
number 
altered genes
Precision 
(%)
Recall 
(%)
F1 score 
(%)
Accuracy 
(%)
Adrenocortical carcinoma (ACC) 88 6,904 12,725 96.10 84.09 89.70 84.09
Bladder urothelial carcinoma (BLCA) 127 11,674 11,223 92.04 63.78 75.35 62.20
Breast invasive carcinoma (BRCA) 967 15,716 12,178 83.19 92.14 87.44 92.86
Cervical and endocervical cancers (CESC) 191 12,165 11,505 69.63 68.06 68.84 71.89
Cholangiocarcinoma (CHOL) 35 3,511 9,707 73.68 40.00 51.85 31.43
Colorectal adenocarcinoma (COADREAD) 220 14,941 11,509 87.73 87.73 87.73 88.18
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) 48 6,457 9,475 90.91 62.50 74.07 58.33
Esophageal carcinoma (ESCA) 184 13,557 1,1534 81.18 58.70 68.35 63.04
Glioblastoma multiforme (GBM) 280 8,069 11,410 81.85 88.57 85.08 89.64
Head and Neck squamous cell carcinoma (HNSC) 279 12,783 11,270 70.65 74.19 72.38 77.42
Kidney Chromophobe (KICH) 66 3,698 10,431 96.49 83.33 89.43 83.33
Kidney renal clear cell carcinoma (KIRC) 410 9,900 11,562 88.36 94.39 91.27 94.39
Kidney renal papillary cell carcinoma (KIRP) 161 7,332 10,568 83.23 80.12 81.65 78.88
Acute Myeloid Leukemia (LAML) 182 1,369 7,719 84.50 92.86 88.48 93.41
Brain Lower Grade Glioma (LGG) 280 4,732 10,190 89.88 82.50 86.03 82.86
Liver hepatocellular carcinoma (LIHC) 193 9,985 11,980 81.59 68.91 74.72 66.84
Lung adenocarcinoma (LUAD) 230 13,931 11,071 86.51 80.87 83.60 79.57
Lung squamous cell carcinoma (LUSC) 177 13,487 11,212 73.33 74.58 73.95 78.53
Ovarian serous cystadenocarcinoma (OV) 311 8,435 11,684 81.69 90.35 85.80 91.96
Pancreatic adenocarcinoma (PAAD) 149 10,144 8,744 83.23 89.93 86.45 89.93
Pheochromocytoma and Paraganglioma (PCPG) 166 2,125 10,103 86.78 90.96 88.82 89.16
Prostate adenocarcinoma (PRAD) 331 6,116 9,996 80.16 90.33 84.94 87.61
Sarcoma (SARC) 243 7,416 12,099 86.00 70.78 77.65 69.14
Skin Cutaneous Melanoma (SKCM) 341 17,085 11,883 90.05 92.67 91.54 92.67
Stomach adenocarcinoma (STAD) 286 16,607 11,745 76.09 79.02 77.53 80.77
Testicular Germ Cell Tumors (TGCT) 155 5,904 9,133 91.02 98.07 94.41 98.71
Thyroid carcinoma (THCA) 403 3,910 8,721 85.14 93.80 89.26 93.80
Thymoma (THYM) 121 1,805 9,305 86.14 71.90 78.38 76.03
Uterine Corpus Endometrial Carcinoma (UCEC) 242 18,412 12,133 81.39 77.69 79.49 76.86
Uterine Carcinosarcoma (UCS) 56 5,508 11,611 67.74 37.50 48.28 35.71
Uveal Melanoma (UVM) 80 1,340 9,559 80.00 85.33 82.58 83.75
Total 7,002 22,421 13,040 83.43 78.89 80.49 84.09
Table 1. Cancer type, sample size, number of mutated genes, number of copy number-altered genes, average 
precision, average recall, average F1 score and average classification accuracy of 31 cancer types used in our 
experiment.
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pathway to cell migration, apoptosis, and chromosome segregation23. APC mutations occur in 42% of colorectal 
cancer and 14% of small bowel cancer. KRAS is a well-known oncogene that is commonly found in pancreatic, 
colon, and lung cancers. KRAS induces tumorigenesis, regulates cell degeneration, and induces genomic 
instability.
Even though we already achieved KG high classification average accuracy of up to 84% for 31 cancer types 
from the TCGA database using our ensemble method, the classification accuracy could be increased further by 
focusing on cancer types with a sufficient number of samples. One observation we made is that the size of the 
training data is not evenly distributed across the cancer types in the database. Some cancer types have a very small 
number of training sets, which affects the performance of machine learning (Table 1). For example, we only have 
35 samples for the CHOL cancer type, which resulted in low average accuracy of 31.43%. To circumvent this issue, 
we selected subsets of cancer types based on the number of samples. For cancer types with 200 or more samples, 
we were able to collect 14 cancer types from 4,823 samples and achieved an accuracy of up to 87%, which was 
about 4 percent points higher than using all 31 cancer types (Supplementary Fig. S2). If we increased the thresh-
old to 300 or more samples, then six most frequent cancer types remained (BRCA, KIRC, OV, PRAD, SKCM, and 
THCA), and the classification accuracy further improved to 94%, which was about 10 percentage points higher 
than using all 31 cancer types (Supplementary Fig. S3).
To further demonstrate the wide applicability of the proposed method to other data (i.e., non-TCGA data), we 
trained and tested CPEM using the ICGC (International Cancer Genome Consortium) dataset, which provides 
sequencing data for 76 cancer projects. We collected somatic SNV and CNV data of 48 cancer projects performed 
on at least 10 samples. In this experiment, we used the same nested 10-fold cross-validation used for TCGA data 
to assess the performance. CPEM achieved up to 82.40% accuracy, while the accuracy of neural network and ran-
dom forest are 77.93% and 74.83% in outer 10-fold cross-validation, respectively. This demonstrates that CPEM 
is effective on non-TCGA data as well.
We observed that, even though CPEM demonstrates superior performance on TCGA or ICGC only, its 
cross-platform application is not working well, which is somehow expected in a data-driven approach. For this 
experiment, we collected 124 BRCA, 265 ESCA, 428 PAAD and 451 BRCA samples from the non-TCGA ICGC 
data. Then we directly applied our CPEM trained using only TCGA data to these non-TCGA data, which resulted 
in the classification accuracy of 78.23%, 6.79%, 64.95% and 49.22% for PRAD, ESCA, PAAD and BRCA, respec-
tively. We believe the reason for the poor performance on ESCA and BRCA is due to the platform inhomogeneity. 
According to the ICGC portal web page (https://icgc.org/node/70708), this non-TCGA ESCA data generated by 
Cancer Research UK seem to also include Barrett’s esophagus as well as esophageal cancer. We believe that the 
histological difference between Barrett’s esophagus and esophageal cancer is significant, and this is the reason 
why the TCGA-trained model showed poor performance in predicting non-TCGA ESCA. As for BRCA, we com-
pared histopathological subtypes for the tumor samples of TCGA and Non-TCGA (ICGC). Although there are 
overlapping major histopathological subtypes such as ‘ductal’ and ‘lobular’ carcinoma, there are histopathological 
subtypes that are not perfectly matched with each other. More details of BRCA’s histopathological differences can 
be found in Supplementary Fig. S7. Developing a more robust cancer prediction method for inhomogeneous 
platforms in multi-site or multi-modal data would be an interesting future research direction.
A B A ∩ B A ∪ B A−B B−A Ensemble (A, B)
DNN (A), Random forest (B) 82.25 73.79 67.81 88.23 14.44 5.98 84.09
DNN (A), OvR SVM (B) 82.25 72.85 70.21 84.89 12.04 2.64 80.95
DNN (A), KNN (B) 82.25 48.59 46.30 84.53 35.95 2.29 78.81
Random forest (A), OvR SVM (B) 73.79 72.85 62.58 84.06 11.21 10.27 78.79
Random forest (A), KNN (B) 73.79 48.59 43.87 78.51 29.92 4.71 67.30
OvR SVM (A), KNN (B) 72.85 48.59 44.50 76.94 28.35 4.08 68.41
Table 2. Classification accuracy of various machine learning classifiers and their combinations with LSVC 
feature selection in the outer 10-fold cross validation. This result confirms that the ensemble of a deep neural 
network and a random forest performs best.
# of 
samples
# of 
features
# of cancer 
types Precision Recall F1 score Accuracy
DeepGene13 3122 1200 12 N/A N/A N/A 66.50
*TumorTracer11
2820 232 6 85.83 84.95 85.39 85.00
4975 560 10 72.23 68.98 70.57 69.00
Chen et al.12 6751 101176 18 65.24 62.26 63.72 62.00
*CPEM
2763 4000 6 84.77 90.61 87.59 94.14
4823 4000 14 83.48 85.36 84.41 87.02
7002 4000 31 83.43 78.89 80.49 84.06
Table 3. Comparison between CPEM and previously reported cancer type classification methods.
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Conclusion
We introduced a novel cancer type classification method, CPEM which is based on mutation features and an 
ensemble of machine learning classifiers. We conducted an in-depth study to clarify how various mutation feature 
groups affect the classification accuracy. Extensive investigation of various feature selection and classification 
methods based on machine learning algorithms led to the development of an ensemble model that classified 31 
cancer types from the TCGA database at an average accuracy of 84% and six common cancer types at an average 
accuracy of 94%. The method outperforms the state-of-the-art mutation-based cancer classification methods.
Future plans are to utilize advanced deep neural networks to improve the cancer classification accuracy. 
Another idea we are currently exploring is to group cancer types in a hierarchical manner to reduce the search 
space size. We are also planning to apply our model to liquid biopsy data, such as circulating tumor DNA, and 
cells for primary tumor site prediction. Current liquid biopsy techniques are offered as laboratory-developed 
tests. Our method will be useful for early diagnosis of cancer as these liquid biopsy techniques evolve24. More 
rigorous validations using real clinical datasets will also be done.
Methods
Overview of the Proposed Method. CPEM consists of several data processing stages followed by a 
machine learning-based cancer classification stage, as shown in Fig. 1. The first step is constructing input feature 
vectors for various different types of somatic alterations detected from cancer genomic data to train and test 
machine learning classifiers. Since the input feature vectors are large and sparse (i.e., mostly zero), the next step 
is to reduce the size of the input feature set. This feature selection step is important to reduce the training time of 
the classifiers and also to increase the prediction accuracy by removing redundant and irrelevant features acting 
as noise. We explored several widely used feature selection algorithms25 and empirically chose a method that 
worked best for our dataset. The last step is the classification of the cancer type using machine learning classifiers. 
We employed an ensemble approach by combining a random forest and a deep neural network to maximize the 
classification accuracy. Detailed descriptions of each stage are provided in the following sections.
Feature Construction. The genetic alterations (e.g., mutation spectra, signatures and somatic copy number 
alterations (SCNAs)) often have a unique pattern depending on the cancer type8,9,26. Hence, these characteristics 
are sequentially applied to the subsequent analysis. We collected somatic single nucleotide variants (SNVs) and 
short insertions and deletions (indels) data for 31 TCGA cancer types from the GDAC27 website (Jan 28, 2016). 
We generated a data matrix of 22,421 genes × 7,115 samples that contains the number of protein sequencing 
altering SNVs and indels for each gene and sample. We also downloaded SCNA data from the GDAC website and 
constructed gene-level log2 copy ratio values to use them as additional input features. Mutation rates and muta-
tion spectra/signatures were calculated using SNV data to be used as input features. As a result, we generated a 
data matrix of 35,565 input features × 7,002 samples to develop cancer type classification machine learning mod-
els. A pictorial description of our feature matrix is shown in Fig. 1, and the details of the input feature contents 
are as follows:
•	 22,421 gene-level somatic mutation profile
•	 2 mutation rates ( )andof SNVs indelsMb of mutated genestotal of genes# /1 # #
•	 6 mutation spectra (C > A, C > G, C > T, T > A, T > C, and T > G)
•	 96 mutation signatures ({A, C, G, T} × 6 mutation spectra × {A, C, G, T})
•	 13,040 gene-level log2 copy ratio
We created an initial prediction model using six machine learning models to evaluate the performance of the 
generated features. The initial results showed the highest accuracy in the random forest model. Subsequently, each 
feature was added to predict the accuracy of the initial model to verify the impact of each feature on the model.
Feature Selection. Feature selection is the process of reducing the dimension of the input feature data by 
removing redundant and irrelevant features that do not contribute to the final result. By selecting important fea-
tures only, the classification can be more accurate and training time can be shortened. Various feature selection 
algorithms for genomic data have been proposed in the past25,28.
In this work, we tested several widely used supervised feature selection algorithms, including tree-based, least 
absolute shrinkage and selection operator (LASSO), and LSVC. We finally chose LSVC as the feature selection 
method (the various feature selection methods are compared above in ‘Comparison of Feature selection Methods’).
Tree-based feature selection. The tree-based feature selection method is based on the feature importance calcu-
lated during the training of the decision tree classifier, namely how much the feature contributes to the reduction 
of the overall error (e.g., accuracy or variance) of the classification. Once the importance of each feature is estab-
lished, the features can be sorted and those with low importance can be discarded. In our experiment, we used 
the extremely randomized trees (extra trees)29, a decision forest that avoids the expensive bootstrapping process 
used in the random forest algorithm.
LASSO feature selection. LASSO is a linear regression problem with a L1-norm sparsity term defined as follow:
n
y w x wmin 1
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where xi is the training vector, yi is the predicted vector, and w is the regression coefficient vector.
After solving the minimization problem of Eq. 1, w serves as the importance value to filter the input feature xi. 
The number of selected features can be determined by the level of sparsity of w by changing the α parameter. If w 
is sparse then the small number of features will be selected, and vice versa.
LSVC feature selection. LSVC30 is based on a squared hinge loss function with an L1-norm sparsity term as 
follows:
∑
= ... =n
L f x ymin 1 ( , , ),
(2)w b c k i
k
i i, ; 1, , 1c c
wsubject to
(3)c
k
c
1
1∑ ε≤
=
where f is a linear decision function defined as fc(x) = wcTx + bc for each class c = 1,..., k in k-class. In our experi-
ment, we choose the f as one-vs-rest decision function for multi-class classification. The loss function L is defined 
as follows:
∑= + −
≠
L f x y f x f x( , , ) max (0,1 ( ) ( ))
(4)
i i
c y
c i y i
2
i
i
Since w for each class will be sparse after minimization, important features can be selected by collecting ele-
ments with non-zero w. Similar to LASSO, the total number of selected features is determined by the sparsity of 
w, which can be controlled by changing ε.
Cancer Type Classification. Once feature data are collected and processed, the next step is training machine 
learning classifiers to predict cancer types. Most previous studies used a collection of binary classifiers (i.e., 
one-vs-rest)11,12,31 to predict the cancer types. Popular classifiers are random forests and support vector machine, 
with deep neural networks used most recently13. Rather than relying on one specific classifier, as in the previous 
studies, we proposed to build an ensemble of different machine learning methods, which is a widely used strat-
egy to enhance the classification performance32,33. To achieve this, we tested four widely used machine learning 
classifiers, including random forests, OvR SVM, KNN, and fully connected DNN, and found the best classifiers 
for our ensemble model. To build an ensemble, we used multinomial classifiers rather than binary classifiers, and 
computed the average of the probability of each output to determine the per-label (i.e., cancer type) probability. 
We performed an in-depth analysis of the correlation of output from the classifiers (see ‘Putting it all together: 
CPEM results’ in the Results).
Data availability
The datasets and code used in this study are available on https://github.com/leekanggeun/CPEM.
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